A Retrospective Pilot Comparison Trial Investigating Clinical Outcomes in Cardiac Surgical Patients Who Received Sugammadex Reversal During 2018 to 2021

To compare the number of eligible urgent and elective cardiac surgical patients who could be extubated successfully within 6 hours of surgery and who received sugammadex versus those who did not. This retrospective pilot study compared outcomes in cardiac surgical patients undergoing cardiopulmonary...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cardiothoracic and vascular anesthesia 2023-08, Vol.37 (8), p.1410-1417
Hauptverfasser: Greenberg, Steven B., Ben-Isvy, Noah, Russell, Hyde, Whitney, Hannah, Wang, Chi, Minhaj, Mohammed
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1417
container_issue 8
container_start_page 1410
container_title Journal of cardiothoracic and vascular anesthesia
container_volume 37
creator Greenberg, Steven B.
Ben-Isvy, Noah
Russell, Hyde
Whitney, Hannah
Wang, Chi
Minhaj, Mohammed
description To compare the number of eligible urgent and elective cardiac surgical patients who could be extubated successfully within 6 hours of surgery and who received sugammadex versus those who did not. This retrospective pilot study compared outcomes in cardiac surgical patients undergoing cardiopulmonary bypass between 2018 to 2021 who received sugammadex versus those who did not. At a tertiary-care hospital in the Northshore of Chicago. A total of 358 elective or urgent cardiac surgical patients who underwent cardiopulmonary bypass (by 1 cardiac surgeon) and were extubated within 24 hours of the end of surgery at Evanston Hospital in Evanston, IL, were included. Data were examined in the following 2 groups of patients: those who were administered sugammadex and those who were not. After performing propensity matching for age, sex, body mass index, kidney or liver disease, the number of preoperative conditions (defined as the sum of the presence of the following medical conditions: diabetes, immunosuppressive disease, on home oxygen, on inhaled bronchodilator, or sleep apnea), number of patients who underwent elective or urgent surgery in each group, surgery time, cardiopulmonary bypass duration, number of intraoperative blood products, use of intraoperative midazolam and propofol, a statistically significant increase in the percentage of patients in the sugammadex group were extubated within 6 hours of the end of surgery versus those who did not receive sugammadex (96.67% v 81.33%, p = 0.0428). In addition, there was a statistically significant reduction in time to extubation (hours) (4.72 ± 2.92) v (3.57± 1.96 p = 0.0098) in the sugammadex group. All other outcomes did not meet statistical significance. This retrospective study suggested that using sugammadex reversal in cardiac surgical patients undergoing cardiopulmonary bypass may result in more patients meeting the Society of Thoracic Surgery benchmark extubation criteria within 6 hours of the end of surgery.
doi_str_mv 10.1053/j.jvca.2023.03.030
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2807913206</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1053077023002008</els_id><sourcerecordid>2807913206</sourcerecordid><originalsourceid>FETCH-LOGICAL-c307t-16c0e50bd6db0db6b8ef88ab051919b0207e03bf14c18bb4b7836a558ac452413</originalsourceid><addsrcrecordid>eNp9kc9u1DAQxiMEoqXwAhyQj1yyjJ048UpcqpQ_lSq1giKOlu3MLl4l8WI7EbwJj8uELRyRRhpr5jefNfMVxUsOGw6yenPYHBZnNgJEtYE14FFxzmUlSlUL8ZjeRJXQtnBWPEvpAMC5lO3T4qxqqaUkPy9-XbJPmGNIR3TZL8ju_BAy68J4NNGnMLH76M3ArqcFU_Z7k_20Z93gJ--ofDtnF0ZMzE-sM7H3xrHPc9z_ad4RjFNO7Ou3QL84JP2e2nszjqbHH1RbMCYir-a4ygrgiuVAWfDnxZOdGRK-eMgXxZf37-67j-XN7Yfr7vKmdBW0ueSNA5Rg-6a30NvGKtwpZSxIvuVbCwJahMrueO24sra2raoaI6Uyrpai5tVF8fqke4zh-0w76tEnh8NgJgxz0kJBu-WVgIZQcUId3StF3Olj9KOJPzUHvd5aH_TqiF4d0bAG0NCrB_3Zjtj_G_lrAQFvTwDSlovHqJOjsznsfSRPdB_8__R_A0xVnRs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2807913206</pqid></control><display><type>article</type><title>A Retrospective Pilot Comparison Trial Investigating Clinical Outcomes in Cardiac Surgical Patients Who Received Sugammadex Reversal During 2018 to 2021</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Greenberg, Steven B. ; Ben-Isvy, Noah ; Russell, Hyde ; Whitney, Hannah ; Wang, Chi ; Minhaj, Mohammed</creator><creatorcontrib>Greenberg, Steven B. ; Ben-Isvy, Noah ; Russell, Hyde ; Whitney, Hannah ; Wang, Chi ; Minhaj, Mohammed</creatorcontrib><description>To compare the number of eligible urgent and elective cardiac surgical patients who could be extubated successfully within 6 hours of surgery and who received sugammadex versus those who did not. This retrospective pilot study compared outcomes in cardiac surgical patients undergoing cardiopulmonary bypass between 2018 to 2021 who received sugammadex versus those who did not. At a tertiary-care hospital in the Northshore of Chicago. A total of 358 elective or urgent cardiac surgical patients who underwent cardiopulmonary bypass (by 1 cardiac surgeon) and were extubated within 24 hours of the end of surgery at Evanston Hospital in Evanston, IL, were included. Data were examined in the following 2 groups of patients: those who were administered sugammadex and those who were not. After performing propensity matching for age, sex, body mass index, kidney or liver disease, the number of preoperative conditions (defined as the sum of the presence of the following medical conditions: diabetes, immunosuppressive disease, on home oxygen, on inhaled bronchodilator, or sleep apnea), number of patients who underwent elective or urgent surgery in each group, surgery time, cardiopulmonary bypass duration, number of intraoperative blood products, use of intraoperative midazolam and propofol, a statistically significant increase in the percentage of patients in the sugammadex group were extubated within 6 hours of the end of surgery versus those who did not receive sugammadex (96.67% v 81.33%, p = 0.0428). In addition, there was a statistically significant reduction in time to extubation (hours) (4.72 ± 2.92) v (3.57± 1.96 p = 0.0098) in the sugammadex group. All other outcomes did not meet statistical significance. This retrospective study suggested that using sugammadex reversal in cardiac surgical patients undergoing cardiopulmonary bypass may result in more patients meeting the Society of Thoracic Surgery benchmark extubation criteria within 6 hours of the end of surgery.</description><identifier>ISSN: 1053-0770</identifier><identifier>EISSN: 1532-8422</identifier><identifier>DOI: 10.1053/j.jvca.2023.03.030</identifier><identifier>PMID: 37105851</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Cardiac surgery ; Cardiac Surgical Procedures ; Female ; Humans ; Male ; Neuromuscular Blockade ; Outcomes ; Pilot Projects ; Retrospective Studies ; Reversal ; Sugammadex - therapeutic use</subject><ispartof>Journal of cardiothoracic and vascular anesthesia, 2023-08, Vol.37 (8), p.1410-1417</ispartof><rights>2023 Elsevier Inc.</rights><rights>Copyright © 2023 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c307t-16c0e50bd6db0db6b8ef88ab051919b0207e03bf14c18bb4b7836a558ac452413</cites><orcidid>0000-0003-2529-5637</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1053/j.jvca.2023.03.030$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37105851$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Greenberg, Steven B.</creatorcontrib><creatorcontrib>Ben-Isvy, Noah</creatorcontrib><creatorcontrib>Russell, Hyde</creatorcontrib><creatorcontrib>Whitney, Hannah</creatorcontrib><creatorcontrib>Wang, Chi</creatorcontrib><creatorcontrib>Minhaj, Mohammed</creatorcontrib><title>A Retrospective Pilot Comparison Trial Investigating Clinical Outcomes in Cardiac Surgical Patients Who Received Sugammadex Reversal During 2018 to 2021</title><title>Journal of cardiothoracic and vascular anesthesia</title><addtitle>J Cardiothorac Vasc Anesth</addtitle><description>To compare the number of eligible urgent and elective cardiac surgical patients who could be extubated successfully within 6 hours of surgery and who received sugammadex versus those who did not. This retrospective pilot study compared outcomes in cardiac surgical patients undergoing cardiopulmonary bypass between 2018 to 2021 who received sugammadex versus those who did not. At a tertiary-care hospital in the Northshore of Chicago. A total of 358 elective or urgent cardiac surgical patients who underwent cardiopulmonary bypass (by 1 cardiac surgeon) and were extubated within 24 hours of the end of surgery at Evanston Hospital in Evanston, IL, were included. Data were examined in the following 2 groups of patients: those who were administered sugammadex and those who were not. After performing propensity matching for age, sex, body mass index, kidney or liver disease, the number of preoperative conditions (defined as the sum of the presence of the following medical conditions: diabetes, immunosuppressive disease, on home oxygen, on inhaled bronchodilator, or sleep apnea), number of patients who underwent elective or urgent surgery in each group, surgery time, cardiopulmonary bypass duration, number of intraoperative blood products, use of intraoperative midazolam and propofol, a statistically significant increase in the percentage of patients in the sugammadex group were extubated within 6 hours of the end of surgery versus those who did not receive sugammadex (96.67% v 81.33%, p = 0.0428). In addition, there was a statistically significant reduction in time to extubation (hours) (4.72 ± 2.92) v (3.57± 1.96 p = 0.0098) in the sugammadex group. All other outcomes did not meet statistical significance. This retrospective study suggested that using sugammadex reversal in cardiac surgical patients undergoing cardiopulmonary bypass may result in more patients meeting the Society of Thoracic Surgery benchmark extubation criteria within 6 hours of the end of surgery.</description><subject>Cardiac surgery</subject><subject>Cardiac Surgical Procedures</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Neuromuscular Blockade</subject><subject>Outcomes</subject><subject>Pilot Projects</subject><subject>Retrospective Studies</subject><subject>Reversal</subject><subject>Sugammadex - therapeutic use</subject><issn>1053-0770</issn><issn>1532-8422</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc9u1DAQxiMEoqXwAhyQj1yyjJ048UpcqpQ_lSq1giKOlu3MLl4l8WI7EbwJj8uELRyRRhpr5jefNfMVxUsOGw6yenPYHBZnNgJEtYE14FFxzmUlSlUL8ZjeRJXQtnBWPEvpAMC5lO3T4qxqqaUkPy9-XbJPmGNIR3TZL8ju_BAy68J4NNGnMLH76M3ArqcFU_Z7k_20Z93gJ--ofDtnF0ZMzE-sM7H3xrHPc9z_ad4RjFNO7Ou3QL84JP2e2nszjqbHH1RbMCYir-a4ygrgiuVAWfDnxZOdGRK-eMgXxZf37-67j-XN7Yfr7vKmdBW0ueSNA5Rg-6a30NvGKtwpZSxIvuVbCwJahMrueO24sra2raoaI6Uyrpai5tVF8fqke4zh-0w76tEnh8NgJgxz0kJBu-WVgIZQcUId3StF3Olj9KOJPzUHvd5aH_TqiF4d0bAG0NCrB_3Zjtj_G_lrAQFvTwDSlovHqJOjsznsfSRPdB_8__R_A0xVnRs</recordid><startdate>202308</startdate><enddate>202308</enddate><creator>Greenberg, Steven B.</creator><creator>Ben-Isvy, Noah</creator><creator>Russell, Hyde</creator><creator>Whitney, Hannah</creator><creator>Wang, Chi</creator><creator>Minhaj, Mohammed</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2529-5637</orcidid></search><sort><creationdate>202308</creationdate><title>A Retrospective Pilot Comparison Trial Investigating Clinical Outcomes in Cardiac Surgical Patients Who Received Sugammadex Reversal During 2018 to 2021</title><author>Greenberg, Steven B. ; Ben-Isvy, Noah ; Russell, Hyde ; Whitney, Hannah ; Wang, Chi ; Minhaj, Mohammed</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c307t-16c0e50bd6db0db6b8ef88ab051919b0207e03bf14c18bb4b7836a558ac452413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Cardiac surgery</topic><topic>Cardiac Surgical Procedures</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Neuromuscular Blockade</topic><topic>Outcomes</topic><topic>Pilot Projects</topic><topic>Retrospective Studies</topic><topic>Reversal</topic><topic>Sugammadex - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Greenberg, Steven B.</creatorcontrib><creatorcontrib>Ben-Isvy, Noah</creatorcontrib><creatorcontrib>Russell, Hyde</creatorcontrib><creatorcontrib>Whitney, Hannah</creatorcontrib><creatorcontrib>Wang, Chi</creatorcontrib><creatorcontrib>Minhaj, Mohammed</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cardiothoracic and vascular anesthesia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Greenberg, Steven B.</au><au>Ben-Isvy, Noah</au><au>Russell, Hyde</au><au>Whitney, Hannah</au><au>Wang, Chi</au><au>Minhaj, Mohammed</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Retrospective Pilot Comparison Trial Investigating Clinical Outcomes in Cardiac Surgical Patients Who Received Sugammadex Reversal During 2018 to 2021</atitle><jtitle>Journal of cardiothoracic and vascular anesthesia</jtitle><addtitle>J Cardiothorac Vasc Anesth</addtitle><date>2023-08</date><risdate>2023</risdate><volume>37</volume><issue>8</issue><spage>1410</spage><epage>1417</epage><pages>1410-1417</pages><issn>1053-0770</issn><eissn>1532-8422</eissn><abstract>To compare the number of eligible urgent and elective cardiac surgical patients who could be extubated successfully within 6 hours of surgery and who received sugammadex versus those who did not. This retrospective pilot study compared outcomes in cardiac surgical patients undergoing cardiopulmonary bypass between 2018 to 2021 who received sugammadex versus those who did not. At a tertiary-care hospital in the Northshore of Chicago. A total of 358 elective or urgent cardiac surgical patients who underwent cardiopulmonary bypass (by 1 cardiac surgeon) and were extubated within 24 hours of the end of surgery at Evanston Hospital in Evanston, IL, were included. Data were examined in the following 2 groups of patients: those who were administered sugammadex and those who were not. After performing propensity matching for age, sex, body mass index, kidney or liver disease, the number of preoperative conditions (defined as the sum of the presence of the following medical conditions: diabetes, immunosuppressive disease, on home oxygen, on inhaled bronchodilator, or sleep apnea), number of patients who underwent elective or urgent surgery in each group, surgery time, cardiopulmonary bypass duration, number of intraoperative blood products, use of intraoperative midazolam and propofol, a statistically significant increase in the percentage of patients in the sugammadex group were extubated within 6 hours of the end of surgery versus those who did not receive sugammadex (96.67% v 81.33%, p = 0.0428). In addition, there was a statistically significant reduction in time to extubation (hours) (4.72 ± 2.92) v (3.57± 1.96 p = 0.0098) in the sugammadex group. All other outcomes did not meet statistical significance. This retrospective study suggested that using sugammadex reversal in cardiac surgical patients undergoing cardiopulmonary bypass may result in more patients meeting the Society of Thoracic Surgery benchmark extubation criteria within 6 hours of the end of surgery.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>37105851</pmid><doi>10.1053/j.jvca.2023.03.030</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-2529-5637</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1053-0770
ispartof Journal of cardiothoracic and vascular anesthesia, 2023-08, Vol.37 (8), p.1410-1417
issn 1053-0770
1532-8422
language eng
recordid cdi_proquest_miscellaneous_2807913206
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Cardiac surgery
Cardiac Surgical Procedures
Female
Humans
Male
Neuromuscular Blockade
Outcomes
Pilot Projects
Retrospective Studies
Reversal
Sugammadex - therapeutic use
title A Retrospective Pilot Comparison Trial Investigating Clinical Outcomes in Cardiac Surgical Patients Who Received Sugammadex Reversal During 2018 to 2021
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T05%3A33%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Retrospective%20Pilot%20Comparison%20Trial%20Investigating%20Clinical%20Outcomes%20in%20Cardiac%20Surgical%20Patients%20Who%20Received%20Sugammadex%20Reversal%20During%202018%20to%202021&rft.jtitle=Journal%20of%20cardiothoracic%20and%20vascular%20anesthesia&rft.au=Greenberg,%20Steven%20B.&rft.date=2023-08&rft.volume=37&rft.issue=8&rft.spage=1410&rft.epage=1417&rft.pages=1410-1417&rft.issn=1053-0770&rft.eissn=1532-8422&rft_id=info:doi/10.1053/j.jvca.2023.03.030&rft_dat=%3Cproquest_cross%3E2807913206%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2807913206&rft_id=info:pmid/37105851&rft_els_id=S1053077023002008&rfr_iscdi=true